Time filter

Source Type

Basingstoke, United Kingdom

Yonemura Y.,Peritoneal Surface Malignancy Center | Canbay E.,NPO to Support Peritoneal Surface Malignancy Treatment | Li Y.,Capital Medical University | Coccolini F.,General Surgery Papa Giovanni XXIII Hospital | And 12 more authors.
European Journal of Surgical Oncology | Year: 2016

Recently, Peritoneal Surface Oncology Group International (PSOGI) developed a novel comprehensive treatment consisting of cytoreductive surgery (CRS) and perioperative chemotherapy (POC) for the treatment of peritoneal metastases (PM) from gastric cancer with curative intent. This article reviews the results of this treatment and verifies its indication.In this strategy, peritoneal cancer index (PCI) is determined by laparoscopy, and a peritoneal port is placed. Neoadjuvant bidirectional intraperitoneal/systemic chemotherapy (NIPS) is performed for 3 cycles, and then laparotomy is performed. Cytoreductive surgery with peritonectomy procedures and hyperthermic intraperitoneal chemoperfusion (HIPEC) are performed.Multivariate analyses showed that completeness of cytoreduction, pathologic response to NIPS and PCI level and cytologic status after NIPS, as independent prognostic factors. PCI less than cut-off level after NIPS, negative cytology after NIPS, and positive response to NIPS were identified as the indications for comprehensive treatment. Patients who hold these criteria should be considered as the candidates for CRS and HIPEC. © 2016 Elsevier Ltd. Source

Moran B.J.,Peritoneal Malignancy Institute Basingstoke | Cecil T.D.,Peritoneal Malignancy Institute Basingstoke
British Journal of Surgery | Year: 2014

Need for centres and training standards © 2013 BJS Society Ltd. Published by John Wiley & Sons Ltd. Source

Discover hidden collaborations